Last updated on April 24, 2014 at 0:13 EDT

Latest Evofem LLC Stories

2013-07-24 12:29:08

Innovative CRO Health Decisions extends track record of enrolling largest-ever trial of its type ahead of schedule. DURHAM, N.C, July 24, 2013 /PRNewswire-iReach/ -- Health Decisions, Inc., the leading clinical research organization focusing on efficiency in execution of clinical development, today announced early completion of enrollment for a 3,384-subject phase III registration study of Evofem LLC's Amphora® nonhormonal contraceptive gel. (Photo:...

2013-07-23 08:31:48

SAN DIEGO, July 23, 2013 /PRNewswire/ -- Evofem is pleased to announce the early completion of enrollment for their 3,200-subject Phase III registration study of Amphora® non-hormonal contraceptive gel. (Logo: http://photos.prnewswire.com/prnh/20130304/CG70327LOGO) The global trial compares Amphora to Conceptrol®, the brand name of Nonoxynol-9, and the only spermicidal gel currently approved by the FDA. "We are very pleased with the progress on the development of...